Interleukin-2 inhibitors in autoimmune disease
Interleukin-2 inhibitors in autoimmune disease
复制标题
DOI：
10.1517/13543776.9.1.27
复制
发表时间：
1999
影响因子：
6.6
通讯作者：
M. Palanki;A. Manning
中科院分区：
文献类型：
--
作者：
M. Palanki;A. Manning
T-lymphocytes orchestrate both the initiation and propagation of immune responses largely through the secretion of interleukin-2 (IL-2). IL-2 is primarily involved in the regulation of T-lymphocytes proliferation but also activates natural killer (NK), B- and lymphokine-activated killer (LAK) cells. Inappropriate responses of T-lymphocytes are associated with a range of immune diseases, including allergies and autoimmune diseases. Because of the key role of IL-2 in promoting the growth of T-cells involved in autoimmune disease, there is significant interest in inhibition of IL-2 as a therapeutic modality. Compounds such as cyclosporin A (CsA), rapamycin and FK506 from microbial sources are mainly used to combat transplant rejection. Several compounds, including leflunomide and mycophenolate mofetil were developed to selectively inhibit nucleotide synthesis in T-cells and hence block IL-2 synthesis. Several patents have claimed the use of peptides and antibodies to inhibit IL-2 and T-cell activation. Alter...
